|
Welcome to the Formulation Design & Development Section |
 |
Affiliated Focus Groups
Animal
Pharmaceutics & Technology
Dermatopharmaceutics
Excipients
Generic
Pharmaceuticals
Inhalation
and Nasal Technology
Lipid-Based
Drug Delivery Systems
Modified
Release
Nanotechnology
Nucleic Acid Based Therapeutics
Nutraceutical
Ocular
Drug Delivery & Disposition
Preformulation
Process Development
Sterile
Products
Formulation Design & Development
The Formulation Design & Development Section is comprised of members from many
diverse backgrounds in industry, regulatory and academia who share a common interest
in the area of formulation design, research and development - a multidisciplinary
field drawing upon the physical, chemical, biological and engineering sciences.
The primary goal of this section is to unite multiple scientific disciplines in
a forum where they can share experimental results, consider new formulation and
dosage form technologies, and discuss issues and concerns regarding the design and
development of formulations/drug products for all dosage forms. This Section collaboratively
interfaces with other sections which focus on pre-formulation, biopharmaceutics,
formulation strategies, and manufacturing process optimization.
Aspects of formulation design and development include the study of dosage forms
for drug delivery via all routes of administration wherein the dosage form encompasses
the formulation, process by which it is made, and primary packaging. The Section’s
focus on development includes product design, delivery systems and technology, stability,
quality, and performance both in vitro and in vivo that is appropriate to its development
stage.
FDD Section Vision
The Formulation Design and Development Section will be the premier worldwide forum
for scientists dedicated to the design and development of all dosage forms.
FDD Section Mission
The Formulation Design and Development Section provides a dynamic international
forum for the exchange of formulation-related knowledge among scientists to enhance
their contributions to health. We offer timely formulation-related scientific programs,
on-going education, opportunities for networking, and professional development by:
- Providing forums for the free interchange and dissemination of scientific knowledge,
particularly in the area of formulation design and development;
- Fostering the scientific and technical growth of scientists in the discipline;
- Promoting and recognizing excellence in the discipline;
- Encouraging the support of basic academic, industrial, and regulatory research programs
and the development of mutually beneficial relationships;
- Encouraging students to enter the discipline by strengthening and increasing the
viability of academic programs in formulation design and development;
- Collaborating with and supporting other AAPS sections, focus groups, and other professional/scientific
organizations; and
- Informing the public of major advances in formulation design and development.
FDD By-Laws
|
FDD Newsletter
Please check back frequently for more information about the brand new FDD Section!
The archived websites for the Pharmaceutics
and Drug Delivery (PDD) Section and the
Pharmaceutical Technologies (PT) Section
are still available for access.
|
|
|
Chair
Mansoor A. Khan, R.Ph., Ph.D.
FDA/CDER/DPQR, HFD-941
Silver Spring, MD UNITED STATES
| Chair-Elect
Colin M. Minchom, Ph.D.
Patheon Inc.
Mississauga, ON Canada
| Vice Chair
Dave Wallick, Ph.D.
The Dow Chemical Company
Midland, MI UNITED STATES
| Secretary/Treasurer
Lori R. Hilden, Ph.D.
Eli Lilly & Company
Indianapolis, IN
| Past Chair
Bradley A. Clark, Ph.D.
Solvay Pharmaceuticals
Marietta, GA
| Member at Large
Peter A. Crooks, Ph.D.
University of Kentucky
College of Pharmacy
Lexington, KY UNITED STATES
| National Biotechnology Conference Screeners Committee
Yoon Yeo
Purdue University
West Lafayette, IN UNITED STATES
| Annual Meeting Screeners Committee
Jayanth Panyam
University of Minnesota
Minneapolis, MN UNITED STATES
| Annual Meeting Program Committee
Colin M. Minchom, Ph.D.
Patheon Inc.
Mississauga, ON Canada
| Annual Meeting Program Committee
Dave Wallick, Ph.D.
The Dow Chemical Company
Midland, MI UNITED STATES
| Awards Committee
Indra K. Reddy, Ph.D.
Texas A&M Health Science Center College of Pharmacy
Kingsville, TX United States
| Content Advisory Cmte
Sandra M. Sims, Ph.D.
Pharmaceutical Development Consulting, LLC
Portage, MI United States
| National Biotech Progrming Committee
Feroz Jameel
Amgen
Thousand Oaks, CA
| Student/Postdoc Committee
John Graham Eley, Ph.D.
Department of Pharmaceutical Sciences
College of Pharmacy
Pocatello, ID UNITED STATES
| Fellows Committee
Abu T.M. Serajuddin, Ph.D.
St. John's University
Flushing, NY United States
| Nominations Committee
Mansoor A. Khan, R.Ph., Ph.D.
FDA/CDER/DPQR, HFD-941
Silver Spring, MD UNITED STATES
| Program Coordination Committee
Colin M. Minchom, Ph.D.
Patheon Inc.
Mississauga, ON Canada
| Strategic Planning
Bhaskara R. Jasti, Ph.D.
University of the Pacific
Stockton, CA United States
| FDA Representative
Vilayat A. Sayeed, Ph.D.
FDA/CDER/OPS/OGD
Monrovia, MD United States
| Webmasters Committee
Dr. Naveen K. Bejugam
SRI International
Menlo Park, CA United States
| Member Strategic Oversight Committee
Rakhi Shah
FDA/CDER/DPQR
Silver spring, MD UNITED STATES
| Communications Committee
Samantha Lai, Ph.D.
Geron Corporation
Mountain View, CA United States
| Student Rep
Vikas Moolchandani, M.S.
University of Maryland, Baltimore
Baltimore, MD United States
| Communications Committee
William Chekan
Capsugel
Peapack, NJ UNITED STATES
| Staff Liaison
Maria Nadeau
AAPS
Arlington, VA UNITED STATES
| Staff Liaison
Peter Inchauteguiz
AAPS
Arlington, VA UNITED STATES
| Animal Pharmaceutics & Technology Focus Group
Krishan Kumar, Ph.D.
Luna NanoWorks
Manalapan, NJ United States
| Dermatopharmaceutics Focus Group
Carryn H. Purdon
Altana Inc
Melville, NY UNITED STATES
| Excipients Focus Group
Otilia M. Koo
Bristol-Myers Squibb Company
New Brunswick, NJ UNITED STATES
| Generic Pharmaceuticals Focus Group
Mei-Ling Chen, Ph.D
Office of Pharmaceutical Science, Food and Drug Administration
Potomac, MD United States
| Inhalation & Nasal Technology Focus Group
Mr. Dennis K. O'Connor
Boehringer Ingelheim Pharmaceuticals, Inc.
Ridgefield, CT UNITED STATES
| Lipid-Based Drug Delivery Systems Focus Group
Paul M. Bummer, Ph.D.
University of Kentucky
Lexington, KY UNITED STATES
| Modified Release Focus Group
Joseph P. Reo, Ph.D.
Schering-Plough Corporation
Lakeland, TN United States
| Nanotechnology Focus Group
Patrick J. Sinko, Ph.D.
Rutgers University College of Pharmacy
Piscataway, NJ UNITED STATES
| Nucleic Acid Based Therapeutics Focus Group
Sean M. Sullivan, Ph.D
Vical, Inc.
San Diego, CA United States
| Nutraceuticals Focus Group
Mary A. Murray, Ph.D.
Nutrilite, Division Of Access Business Group
Buena Park, CA
| Ocular Drug Delivery & Disposition Focus Group
Dr. Brian R. Rohrs
Bausch & Lomb
Rochester, NY UNITED STATES
| Preformulation Focus Group
Tapan K. Das, Ph.D.
Pfizer, St. Louis
Chesterfield, MO United States
| Process Development Focus Group
Victor M. Wong
Wyeth
Pearl River, NY United States
| Sterile Products Focus Group
Lavinia Marina Lewis, Ph.D.
Pfizer
Chesterfield, MO United States
|
|